In this study, the effect of varying doses of conjugated linoleic acid (CLA) on the growth of transplanted hepatoma dRLh-84 cells and the relationship between tumor growth and prostaglandin (PG) E2 production or cyclooxygenase (COX)-2 expression were examined. Donryu rats were fed an experimental diet containing 0, 0.1, 0.5, or 2wt.% CLA for 3wk, and then dRLh-84 cells were transplanted into the liver. Results show that dietary CLA (0.5 and 2wt.%) significantly enhanced the growth of the transplanted hepatoma cells compared to the non-CLA diet group at 20d after cell transplantation. Tumor weight at 10 d after transplantation was also significantly higher in the 2 wt.% CLA group than in non CLA fed rats. Ten days after transplantation, the PGE2 level in the tumor tissue was shown to be depressed in a CLA dose-dependent manner. Cyclooxygenase-2 (COX-2) mRNA expres sion in the tumor also tended to be lower in the CLA group than in the non-CLA diet group 10d after transplantation. Dietary CLA did not affect the tumor phospholipid arachidonic acid level, which is a substrate for PG synthesis. These results indicate that dietary CLA of at least 0.5 wt.% enhances the growth of transplanted dRLh-84 cells in vivo. It is believed that growth promotion of dRLh-84 cells in vivo by CLA cannot be clarified by the PG synthesis dependent mechanism.
Conjugated linoleic acid (CLA) is a generic term for geometric and positional isomers of octadecadienoic acid. It has been reported that CLA has various benefi cial physiological effects, such as the inhibition of chemically induced carcinogenesis in various tissues such as the mammary gland (1-3), skin (4), forestom ach (5) , and intestine (6) . Moreover, it has been re ported that CLA inhibits the proliferation of various cancer cell lines in vitro (7, 8) as well as the prolifera tion or induction of cell death in human liver tumor cell lines such as HepG2, SNU-128, and 7800NJ cells (9 12) . On the other hand, we previously reported that di etary CLA (2 wt.%) enhanced tumor growth of trans planted hepatoma dRLh-84 cells in Donryu rats (13) . This data indicates that a high dose (2 wt.%) of dietary CLA promotes the growth of transplanted dRLh-84 rat hepatoma cells. Most in vivo studies of CLA have been performed beyond 1 wt.% of diet, yet a volume of only 0.1 wt.% dietary CLA was an effective dose to inhibit chemically induced carcinogenesis (1) (2) (3) (4) (5) (6) . However, the effect of lower doses of dietary CLA on transplanted he patoma cells has not been clearly elucidated.
Cyclooxygenase (COX) has been shown to be a key enzyme in the production of prostaglandins (PGs) from arachidonic acid, and two isoforms of COX have been reported (14, 15) . Among them, COX-1 is constitutively expressed in various tissues, while COX-2 is an in ducible enzyme and can be induced by various stimula tors such as lipopolysaccharide, cytokines and growth factors (16, 17) . It has been reported that many cancer cell lines strongly express COX-2 (18, 19) . COX-2 is also highly expressed in hepatocellular carcinoma (HCC) cells and considered to be related to tumor cell differen tiation (20, 21) . Moreover, it has been reported that the elevated levels of PGE2 in tumor tissue are because of high COX-2 expression (22) (23) (24) . Thus, COX-2 expres sion and production of PGE2 are expected to be key reg ulators of hepatocyte and liver tumor cell growth. In this study, we examined the effect of various doses of CLA on transplanted dRLh-84 hepatoma cells and the relationship between tumor growth and PGE2 produc tion or COX-2 expression. (27) .
RESULTS

Growth parameters
At the start of the feeding period, the average weight of rats in each group was set at 153g and there was no significant difference in weight gain and food efficiency among all the dietary groups (data not shown). The weights of heart, kidneys, lungs, and spleen at the end of the feeding period were also comparable among all the dietary groups (data not shown).
The liver weight is presented as weight with or with out tumor (expressed as tumor+ or tumor-) in Table 1 . At 10 and 20d post-injection, a single solid tumor was formed in all injected rats. The tumor-liver weight in creased in a dose dependent manner for the CLA group, irrespective of cell injection. Tumor liver weights in the control rats were significantly higher than the in jected rats, p<0.001. In the injected rats, the tumor+ liver weight tended to be high in the CLA groups, espe -cially for 0.5 and 2 wt.% on day 20 after injection, be -cause tumor weights were generally higher in CLA groups than in the 0 wt.% CLA group (details shown in Table 2 ). Tumor weight Table 2 shows the effect of varying doses of CLA on tumor weight after the transplantation of dRLh-84 cells. In control rats, no liver tumor was found. In in jected rats, the cells formed a single solid tumor on the liver at least 10d after the injection. At that time, tumor weight was slight and not significantly higher in the 0.1 and 0.5 wt.% CLA groups than in the 0 wt.% CLA group. On the other hand, tumor weight in the 2 wt.% CLA rats was more than twofold compared to the 0 wt.%o CLA rats. On day 20 after the injection, tumor weight increased in a dose-dependent manner in the CLA-fed rats and reached a plateau at the 0.5 wt.%o dose. There was no significant difference between the 0.5 and 2 wt.% CLA groups. PGE2 level in the tumor tissue
The effect of CLA on the tumor PGE2 level is shown in Table 3 . On day 10 after injection, the PGE2 level was shown to have decreased in a dose-dependent manner in CLA.-fed rats. The PGE2 level in the 2 wt.% CLA group was less than 12% of the 0 wt.% CLA group and this difference was statistically significant. On day 20 
DISCUSSION
It has been reported that CLA inhibits chemically in duced carcinogenesis in various tissues (1) (2) (3) (4) (5) (6) . In vitro studies show that CLA also inhibits the proliferation of various tumor cell lines derived from various tissues (7, 8) and several human liver cancer cell lines (9) (10) (11) (12) . Conversely, CLA has been reported to cause liver en largement and enhance hepatic ornitine decarboxylase activity in mice (28); consequently, CLA may act as he patocyte proliferator. However, the effects of dietary CLA on hepatic carcinogenesis and liver tumor growth have not been clearly elucidated. Previously, we re vealed that dietary CLA (2 wt.%,) promoted trans planted hepatoma dRLh-84 cell growth in vivo (13) . In this report, we demonstrated that not only 2 wt.%,, but also 0.5 wt.% dietary CLA significantly promoted trans planted dRLh-84 cell growth in vivo. As shown in Table 3 , dietary CLA reduced the PGE2 level in tumor tissue, and it was assumed that the down-regulation of COX-2 mRNA expression partly contributed to the reduction of PGE2. The high expres sion of COX-2 is often recognized in cancerous tissues or cancer cells, and excess PG synthesis is closely related to tumor growth in various tissues, especially in the colon (30) . In addition, COX-2 selective inhibitor has been re ported to bring growth arrest in hepatocellular carci noma (HCC) (31, 32) . Moreover, COX-2 expression is highly recognized in HCC and its intensity is associated with a differentiate phenotype (20, 21, 31, 33) . In this study, dietary CLA inhibited COX-2 mRNA expression and PGE2 level in transplanted cancerous tissue, but did not inhibit its growth. Taken together, PGE2 reduc tion and down-regulation of COX-2 mRNA expression in tumor tissue by CLA did not bring about tumor-re ducing activity in this study.
Here, not only transplanted dRLh-84 cells, but also other cells such as normal hepatocytes, Kupffer cells, and endothelial cells contributed to the accumulation of PG in the tumor. Harris et al. reported that dietary CLA depressed the PGE2 and PGF2 a levels in rat liver under a high n-6 polyunsaturated fatty acid diet (34) . Most of the PGs produced in the liver under normal conditions do not derive from hepatocytes, but rather from nonparenchymal cells (35) , and COX-1 is a domi nant PG synthesis enzyme because of the low expres sion of COX-2 (36). Thereafter, CLA might inhibit not only COX-2, but also COX-1 derived PG synthesis. Currently, the effect of CLA on the production of PGs from isolated hepatocytes or other cells in the liver such as Kupffer cells and endothelial cells, which are major PGE2 producers in normal liver, has not been well char acterized and this remains to be studied. As shown in Table 4 , however, the accumulation of CLA in tumor phospholipids was very low or not signifi cantly different irrespective of CLA feeding and dosage up to 2 wt.%. Hence, it is thought that the accumula tion of CLA is not important to inhibit PG synthesis. The l0t, 12 cCLA was also one of the major isomers in this experiment. This isomer is metabolized to 5c, 8c,12t, 14c eicosatetraenoic acid, and this metabo lite has been reported to act as a powerful competitive inhibitor for the metabolism of arachidonic acid to PG (37) . This CLA metabolite could be a putative candidate for being a PG synthesis inhibitor. In addition, PGs are synthesized from free arachidonic acid derived from membrane phospholipids. Thus, the phospholipid arachidonic acid level is expected to be a key factor in regulating tissue PG level. It has been reported that CLA converted to desaturated and elongated conjugated fatty acid, and is expected to interfere in the n-6 polyun- We previously reported that tumor growth promo tion by dietary CLA (2 wt.%) coincided with the eleva tion of serum tumor necrosis factor (TNF)-a and inter feron (IFN)-y (13). These results suggest that dietary CLA caused an inflammatory response in tumor-bear ing rats. COX-2 expression is well known to be induced by some cytokines like TNF-a and IFN-y (41, 42) . Dietary CLA inhibited PG synthesis as described above on day 10 after injection, but it was considered that the production of inflammatory cytokines induced by di etary CLA might cancel the inhibitory effect of CLA on COX-2 mRNA expression at day 20 after infection. To examine the effects of CLA on the growth of other hepatoma and hepatic carcinogenesis, more studies are needed.
